Stockscreener 앱 받기
1.43
5.93%
0.08
시간 외 거래:
1.44
0.01
+0.70%
전일 마감가:
$1.35
열려 있는:
$1.37
하루 거래량:
245.22K
Relative Volume:
1.63
시가총액:
$33.82M
수익:
-
순이익/손실:
$-22.29M
주가수익비율:
-1.2119
EPS:
-1.18
순현금흐름:
$-17.12M
1주 성능:
-1.38%
1개월 성능:
+21.19%
6개월 성능:
+30.00%
1년 성능:
+13.40%
1일 변동 폭
$1.3539
$1.4856
1주일 범위
$1.31
$1.66
52주 변동 폭
$0.8101
$1.76
엔라이벡스 Stock (ENLV) Company Profile
ENLV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.43 | 32.20M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Enlivex Therapeutics Ltd. stock trendline breakdownPredictive AI Signals for Short-Term Trading - Newser
Enlivex Therapeutics Ltd. stock trend forecastTechnical Safety Zone Pattern Recognition - Newser
Will Enlivex Therapeutics Ltd. stock go up soonQuick Profit Setup with Signal Forecast - Newser
Real time scanner hits for Enlivex Therapeutics Ltd. explainedFree Real Time Stock Movement Analysis - Newser
Using Bollinger Bands to evaluate Enlivex Therapeutics Ltd.3-Day Market Movement Forecast Analysis - Newser
Is a relief rally coming for Enlivex Therapeutics Ltd. holdersTrade Setup Builder with Custom Alerts - Newser
Why Enlivex Therapeutics Ltd. stock attracts strong analyst attentionTrading Watchlist with Real Time Filters - Newser
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 51.7% in July - Defense World
Can Enlivex Therapeutics Ltd. rally from current levelsSmart Entry Watchlist with Daily Analysis - Newser
Is Enlivex Therapeutics Ltd. showing signs of accumulationReal-Time AI Generated Market Forecast - Newser
Key metrics from Enlivex Therapeutics Ltd.’s quarterly dataLong-Term Trend Tracking and Signal Summary - Newser
What candlestick patterns are forming on Enlivex Therapeutics Ltd.Consistent Profit Signals with AI Models - Newser
Risk vs reward if holding onto Enlivex Therapeutics Ltd.Smart Trade Mapping with Entry Details - Newser
Enlivex Therapeutics Ltd. stock momentum explainedBuy Strategy with Smart Exit Timing - Newser
Applying big data sentiment scoring on Enlivex Therapeutics Ltd.Buy Signal System Based on Price Action - Newser
What makes Enlivex Therapeutics Ltd. stock price move sharplyFree AI Powered High Return Stock Calls - Newser
What analysts say about Enlivex Therapeutics Ltd. stockInvest in high-yield stocks with confidence - Jammu Links News
When is Enlivex Therapeutics Ltd. stock expected to show significant growthPhenomenal wealth increase - Jammu Links News
What institutional investors are buying Enlivex Therapeutics Ltd. stockAchieve exceptional returns with expert guidance - Jammu Links News
What are the technical indicators suggesting about Enlivex Therapeutics Ltd.Unlock steady growth with low-risk stocks - Jammu Links News
Enlivex Therapeutics Ltd. Stock Analysis and ForecastCapitalize on fast-moving stock opportunities - Jammu Links News
How many analysts rate Enlivex Therapeutics Ltd. as a “Buy”Maximize your gains with expert trading tips - Jammu Links News
What is Enlivex Therapeutics Ltd. company’s growth strategyStay ahead with daily expert stock picks - Jammu Links News
What are the latest earnings results for Enlivex Therapeutics Ltd.Unlock powerful portfolio optimization tools - Jammu Links News
What catalysts could drive Enlivex Therapeutics Ltd. stock higher in 2025Achieve rapid growth with smart investments - Jammu Links News
Should you wait for a breakout in Enlivex Therapeutics Ltd.Free Capital Growth With Controlled Risk Picks - Newser
Enlivex Therapeutics Ltd. Charts Flash Early Recovery SignalsLow Risk High Return Opportunities Identified - metal.it
Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital - Defense World
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):